Hyderabad: In order to address the shortage of the antiviral drug, Favipiravir to treat mild and moderate COVID19 flu, MSN Laboratories Pvt. Ltd. (MSN Labs), India’s leading integrated pharmaceutical company, announced today the launch of its branded generic, Favilow 800 mg.

MSN Laboratories launch Favilow
MSN Laboratories launch Favilow

The higher strength Favilow 800 mg is priced at 144 INR per tablet and will be available across pharmacies. The field team of MSN Laboratories is also helping out with free home delivery in over 170 cities in coordination with local retail chemists for patient convenience.

“In the light of increasing COVID-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation’s efforts in overcoming the COVID crisis.”

Dr MSN Reddy
CMD, MSN Group

MSN had launched the world’s most affordable branded generic of Favipiravir, Favilow, in August last year, in the strengths of 200 and 400 mg. MSN claims the higher strength will improve patient compliance and experience by effectively reducing the number of tablets a patient requires per day. The launch would also address the shortages and issues faced by the patients in procuring the COVID-19 drug.

“MSN is currently manufacturing more than 1 lac dosage regimen (5 lakh *strips of different strengths of FAVILOW) for the treatment of COVID-19 in last 15 days, and are scaling up the manufacturing volumes to 6-8 lacs dosage regimen (30 lakh strips of different strengths of FAVILOW) by next month.”

Bharat Reddy
Executive Director – MSN Group

The higher strength of Favipiravir 800 mg from MSN has been approved by the Drug Controller General of India (DCGI). MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for FAVILOW 800 mg in its in-house R&D and manufacturing units. The API & FDF of Favilow matches to the International quality standards.

“The MSN team is reaching out to the doctors, hospitals and patients across the country to ensure that Favilow is easily accessible and the current shortage can be addressed efficiently. The Favilow helpline initiative has already served more than 1000 patients by making the drug available from near by chemists.”

Ashish Gupta
Senior Vice President, Domestic Formulation

As the country battles an explosive rise in COVID-19 cases, the availability of antivirals like Remdesivir, Oseltamivir and other key COVID-related drugs is becoming a challenge.

As part of the COVID treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ‘’OSELOW’’. For availability, please contact MSN COVID Helpline at 91005 91030 or email to [email protected]

Also Read: Ryaltris nasal spray to be launched in 17 European Union countries

About the author

TEAMIU

Add Comment

Leave a Comment